Candel Therapeutics (CADL) Revenue & Revenue Breakdown
Candel Therapeutics Revenue Highlights
Candel Therapeutics Revenue by Period
Candel Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $125.00K | - |
| 2021-12-31 | $125.00K | - |
| 2020-12-31 | $125.00K | - |
| 2019-12-31 | $125.00K | - |
Candel Therapeutics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Candel Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.78M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $31.00K | - |
| 2022-09-30 | $31.00K | - |
| 2022-06-30 | $31.00K | - |
| 2022-03-31 | $31.00K | - |
| 2021-12-31 | $31.00K | - |
| 2021-09-30 | $31.00K | - |
| 2021-06-30 | $31.00K | - |
| 2021-03-31 | $31.00K | - |
| 2020-12-31 | $31.00K | - |
| 2020-09-30 | $31.00K | - |
| 2020-06-30 | $31.00K | - |
| 2020-03-31 | $31.00K | - |
Candel Therapeutics generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Candel Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ADAG | Adagene | $18.11M | $833.34K |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| FBRX | Forte Biosciences | - | - |
| ANTX | AN2 Therapeutics | - | - |
| PHVS | Pharvaris | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| ACXP | Acurx Pharmaceuticals | - | - |
| OKYO | OKYO Pharma | - | - |
| TPST | Tempest Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| CADL | Candel Therapeutics | - | - |
| ENOB | Renovaro Biosciences | - | - |
| INDP | Indaptus Therapeutics | - | - |
| PEPG | PepGen | - | - |
CADL Revenue FAQ
What is Candel Therapeutics’s yearly revenue?
Candel Therapeutics's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $125K, representing an increase of 0% compared to 2021. CADL's yearly revenue for 2021 was $125K, representing an increase of 0% compared to 2020.
What is Candel Therapeutics’s quarterly revenue?
Candel Therapeutics's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $1.78M, a 100.00% increase from the previous quarter (Q3 2023), and a 5629.03% increase year-over-year (Q4 2022). CADL's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a -100.00% decrease year-over-year (Q3 2022).
What is Candel Therapeutics’s revenue growth rate?
Candel Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.